Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab
The DOI matches its Crossref record.
Abstract
Natalizumab is a highly effective immunomodulator in the treatment of multiple sclerosis (MS). Treatment with natalizumab has been associated with progressive multifocal leukoencephalopathy (PML), an infection of the central nervous system (CNS) caused by a pathogenic form of the normally benign JC virus (JCV). We searched PubMed and used current data from the natalizumab global safety database to assess risk factors and quantify the risk of PML. Natalizumab treatment duration and prior use of immunosuppressive therapies are established risk factors for development of PML in natalizumab-treated patients. With the development of a reliable and validated assay for detection of antibodies in patients with MS directed against JCV, it is now possible to identify persons who are carriers of JCV. The availability of this assay provides an additional option for risk stratification of PML in patients using or considering natalizumab therapy. Recommendations for clinical management of patients with MS and use of natalizumab are provided based on the presence of these three risk factors. The identification of risk factors that increase the likelihood of PML in natalizumab-treated patients can facilitate benefit–risk discussions between health care professionals and patients. Continued research and data collection will further develop our understanding of PML and the mechanisms by which these risk factors contribute to its development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The safety of vedolizumab for ulcerative colitis and Crohn's disease
Colombel, J.-F., Sands, B. E., Rutgeerts, P., Sandborn, W., Danese, S., D'Haens, G., Panaccione, R., Loftus, E. V., Sankoh, S., Fox, I., et al. (2017) · Gut · doi:10.1136/gutjnl-2015-311079 · Cited by 806
on behalf of the MAGNIMS study group (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.157 · Cited by 473
Evolving concepts in the treatment of relapsing multiple sclerosis
Comi, G., Radaelli, M., & Soelberg Sørensen, P. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32388-1 · Cited by 306
Disease-modifying therapies and infectious risks in multiple sclerosis
Winkelmann, A., Loebermann, M., Reisinger, E. C., Hartung, H.-P., & Zettl, U. K. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.21 · Cited by 254
Consensus guidelines for the diagnosis and treatment of multiple sclerosis
Yamout, B., Alroughani, R., Al-Jumah, M., Khoury, S., Abouzeid, N., Dahdaleh, M., Alsharoqi, I., Inshasi, J., Hashem, S., Zakaria, M., et al. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.787979 · Cited by 25
Metadata
- Authors
- Sørensen, P. S., Bertolotto, A., Edan, G., Giovannoni, G., Gold, R., Havrdova, E., Kappos, L., Kieseier, B. C., Montalban, X., & Olsson, T.
- Venue
- Multiple Sclerosis Journal
- Publisher
- SAGE Publications
- Published
- 2012-02
- Volume
- 18
- Issue
- 2
- Pages
- 143-152
- ISSN
- 1352-4585 (ISSN-L)
- 1477-0970
- OpenAlex
- W2314996545
- Cited by
- 237
- References
- 0
- FWCI
- 20.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. https://app.cochat.ai/papers/10.1177/1352458511435105
- The paper
- Sørensen, P. S., Bertolotto, A., Edan, G., Giovannoni, G., Gold, R., Havrdova, E., Kappos, L., Kieseier, B. C., Montalban, X., & Olsson, T. (2012). Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Multiple Sclerosis Journal. https://doi.org/10.1177/1352458511435105
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.